SML0784
BMS-303141
≥98% (HPLC), ATP citrate lyase inhibitor, powder
Synonym(s):
3,5-Dichloro-2-hydroxy-N-(4-methoxy[1,1′-biphenyl]-3-yl)-benzenesulfonamide
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C19H15Cl2NO4S
CAS Number:
Molecular Weight:
424.30
NACRES:
NA.77
UNSPSC Code:
51111800
MDL number:
Product Name
BMS-303141, ≥98% (HPLC)
Quality Level
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 20 mg/mL, clear
storage temp.
2-8°C
SMILES string
O=S(NC1=C(OC)C=CC(C2=CC=CC=C2)=C1)(C3=C(O)C(Cl)=CC(Cl)=C3)=O
InChI
1S/C19H15Cl2NO4S/c1-26-17-8-7-13(12-5-3-2-4-6-12)9-16(17)22-27(24,25)18-11-14(20)10-15(21)19(18)23/h2-11,22-23H,1H3
InChI key
SIIPNDKXZOTLEA-UHFFFAOYSA-N
Application
BMS-303141 has been used for inhibition of ATP citrate lyase in breast cancer cell lines.
Biochem/physiol Actions
BMS-303141 is a potent inhibitor of ATP citrate lyase (ACL).
BMS-303141 is a potent inhibitor of ATP citrate lyase (ACL). BMS-303141 inhibits lipid synthesis in HepG2 cells with an IC50 of 8 μM, and lowers plasma triglycerides in a murine hyperlipdemia model.
hcodes
pcodes
Hazard Classifications
Aquatic Chronic 4
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Acetyl-CoA carboxylase 1-dependent protein acetylation controls breast cancer metastasis and recurrence
Garcia MR, et al.
Cell Metabolism, 26, 842-855 (2017)
Sanjay R Srivatsan et al.
Science (New York, N.Y.), 367(6473), 45-51 (2019-12-07)
High-throughput chemical screens typically use coarse assays such as cell survival, limiting what can be learned about mechanisms of action, off-target effects, and heterogeneous responses. Here, we introduce "sci-Plex," which uses "nuclear hashing" to quantify global transcriptional responses to thousands
Yi-Jia Li et al.
Cell reports, 39(9), 110870-110870 (2022-06-02)
Overcoming resistance to chemotherapies remains a major unmet need for cancers, such as triple-negative breast cancer (TNBC). Therefore, mechanistic studies to provide insight for drug development are urgently needed to overcome TNBC therapy resistance. Recently, an important role of fatty